OpenAI Launches GPT-Rosalind for Life Sciences Research
OpenAI released GPT-Rosalind, an AI model built specifically for biology, drug discovery, and translational medicine research. The system is now available as a research preview in ChatGPT, Codex, and via API for selected customers.
The model addresses a concrete problem in pharmaceutical development. Drug approval in the U.S. takes 10 to 15 years, with early-stage research slowed by the need to synthesize large volumes of data, published literature, and experimental results. GPT-Rosalind is designed to help researchers generate hypotheses, plan experiments, and organize evidence across multiple research steps.
OpenAI named the system after Rosalind Franklin, the British chemist whose X-ray crystallography work revealed DNA's structure and established foundations for modern molecular biology.
Available Tools and Partner Rollout
OpenAI is rolling out a free Life Sciences research plugin for Codex that connects scientists to more than 50 tools and data sources. The company is also partnering with Amgen, Moderna, and Thermo Fisher Scientific to integrate GPT-Rosalind into their research and development workflows.
The launch reflects growing demand from pharmaceutical companies, academic institutions, and biotech firms for AI tools that accelerate drug discovery timelines.
Scientists looking to understand how AI applies to research workflows may benefit from AI for Science & Research training resources that cover research automation, data modeling, and laboratory optimization.
Your membership also unlocks:
